Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
OncoTargets and Therapy2017Vol. Volume 10, pp. 4239–4250
Citations Over TimeTop 13% of 2017 papers
Ben Creelan, Dmitry I. Gabrilovich, Jhanelle E. Gray, Charles C. Williams, Tawee Tanvetyanon, Eric B. Haura, Jeffrey S. Weber, Geoffrey T. Gibney, Joseph Markowitz, Joel W. Proksch, Scott A. Reisman, Mark D. McKee, Melanie Chin, Colin J. Meyer, Scott J. Antonia
Abstract
Omaveloxolone has favorable tolerability at biologically active doses, although this trial had a small sample size which limits definitive conclusions. These findings support further investigation of omaveloxolone in cancer.
Related Papers
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study(2022)4 cited
- Tolerability of topical antimicrobials in treatment of acne vulgaris.(2014)
- → Place of Voltaren in clinical practice: emphasis on its tolerability(2009)1 cited
- → TOPICAL MEDICINES IN THE TREATMENT OF ALLERGODERMATHOSIS(2017)